Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10473136 | 0.80 | KMT2A (0.34) | — | |
| SCHEMBL24804924 | 0.77 | L3MBTL1 (0.32) | L3MBTL1HCAR3HCAR2ALDH1A1GAA | |
| SCHEMBL2737328 | 0.76 | ALDH1A1 (0.35) | ALDH1A1GAA | |
| SCHEMBL23401706 | 0.76 | ALDH1A1 (0.36) | L3MBTL1HCAR3HCAR2ALDH1A1GAA | |
| SCHEMBL18774936 | 0.75 | AAK1 (0.33) | — | |
| SCHEMBL678753 | 0.74 | SMN1; SMN2 (0.37) | — | |
| SCHEMBL23399207 | 0.74 | CNR1 (0.41) | HCAR3ALDH1A1 | |
| SCHEMBL173200 | 0.73 | — | — | |
| SCHEMBL12248406 | 0.73 | RECQL (0.33) | — | |
| SCHEMBL22882519 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023118576-A1 | DHODH INHIBITORS CONTAINING A CARBOXYLIC ACID BIOISOSTERE | IMMUNIC AG (DE) | 2023-06-29 | — | — | WO | disclosed |
| US-20220160686-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2022-05-26 | — | — | US | disclosed |
| EP-3828159-A1 | STORAGE AND TRANSPORT STABILIZERS FOR POLYMERIZABLE COMPOUNDS | BASF SE (DE) | 2021-06-02 | — | — | EP | disclosed |
| US-10912755-B2 | Arginase inhibitors and their therapeutic applications | Oncoarendi Therapeutics S.A. (PL) | 2021-02-09 | — | — | US | disclosed |
| US-10787442-B2 | Modulators of indoleamine 2,3-dioxygenase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-09-29 | — | — | US | disclosed |
| US-10730842-B2 | Small molecule inhibitors of DYRK1A and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2020-08-04 | — | — | US | disclosed |
| US-20200131144-A1 | AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS | PHENEX-FXR GMBH (DE) | 2020-04-30 | — | — | US | disclosed |
| US-20200115357-A1 | LIVER X RECEPTORS (LXR) MODULATORS | PHENEX-FXR GMBH (DE) | 2020-04-16 | — | — | US | disclosed |
| US-20190322652-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-24 | — | — | US | disclosed |
| US-9796696-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20080015231-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2008-01-17 | — | — | US | disclosed |
| US-20070293561-A1 | 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid; Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists | ALLERGAN, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070281981-A1 | Glaucoma; 3-substituted pyrrolidine compounds; prostaglandin receptor modulators | ALLERGAN, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070270387-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ALLERGAN, INC | 2007-11-22 | — | — | US | disclosed |
| US-20070265321-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2007-11-15 | — | — | US | disclosed |
| US-20070259929-A1 | Therapeutic Compounds | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259947-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259947-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259836-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070021555-A1 | Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds | ELAN PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281981-A1 | Glaucoma; 3-substituted pyrrolidine compounds; prostaglandin receptor modulators | PTGIR, PTGIS, PTGS1 | L3MBTL1 4883/4885HCAR3 170/4885HCAR2 183/4885 |
| US-10730842-B2 | Small molecule inhibitors of DYRK1A and uses thereof | DYRK1A, DYRK2, DYRK1B | L3MBTL1 3295/4885HCAR3 1652/4885HCAR2 1436/4885 |
| US-20070259836-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | PTGIS, PTGIR, CYP11B2 | L3MBTL1 4794/4885HCAR3 889/4885HCAR2 499/4885 |
| US-20070293561-A1 | 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid; Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists | PTGIR, PTGIS, PTGER2 | L3MBTL1 4849/4885HCAR3 913/4885HCAR2 288/4885 |
| US-20070259929-A1 | Therapeutic Compounds | PIGO, CYC1, COXFA4L2 | L3MBTL1 3867/4885HCAR3 759/4885HCAR2 829/4885 |
| US-10787442-B2 | Modulators of indoleamine 2,3-dioxygenase | IDO1, IDO2, TPH1 | L3MBTL1 4467/4885HCAR3 866/4885HCAR2 157/4885 |
| US-20070259947-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, MMP8 | L3MBTL1 4299/4885HCAR3 2017/4885HCAR2 2483/4885 |
| US-20220160686-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | EED, EZH2, BMI1 | L3MBTL1 567/4885HCAR3 2591/4885HCAR2 2989/4885 |
| US-20070265321-A1 | THERAPEUTIC COMPOUNDS | ACER2, SLC10A1, ASAH2 | L3MBTL1 3886/4885HCAR3 999/4885HCAR2 1153/4885 |
| US-20070270387-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ABCB1, CYP11B2, SLC10A1 | L3MBTL1 4690/4885HCAR3 795/4885HCAR2 613/4885 |
| US-10912755-B2 | Arginase inhibitors and their therapeutic applications | ARG1, ARG2, ARGLU1 | L3MBTL1 3934/4885HCAR3 718/4885HCAR2 193/4885 |
| US-20200131144-A1 | AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS | NR1H2, NR1H3, NR1H4 | L3MBTL1 2981/4885HCAR3 189/4885HCAR2 166/4885 |
| US-20190322652-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, TPH1 | L3MBTL1 4467/4885HCAR3 866/4885HCAR2 157/4885 |
| US-20080015231-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, COXFA4L2 | L3MBTL1 4522/4885HCAR3 2639/4885HCAR2 2933/4885 |
| US-20200115357-A1 | LIVER X RECEPTORS (LXR) MODULATORS | NR1H2, NR1H3, NR1H4 | L3MBTL1 3130/4885HCAR3 107/4885HCAR2 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.